Ocular side effects possibly associated with isotretinoin usage

American Journal of Ophthalmology

Volumn 132, Issue 3, 2001, Pages 299-305

  Fraunfelder, F T ^a,c   Fraunfelder, F W ^a   Edwards, Ralph ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c CASEY EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN;

ACNE; ADOLESCENT; ADULT; ARTICLE; ATROPHY; BLEPHARITIS; CASE REPORT; COLOR VISION DEFECT; CONJUNCTIVITIS; CONTACT LENS; CORNEA OPACITY; DARK ADAPTATION; DRY EYE; EYE DISEASE; EYE MALFORMATION; FEMALE; HUMAN; KERATITIS; KERATOCONJUNCTIVITIS SICCA; LACRIMAL FLUID; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MEIBOMIAN GLAND; MYOPIA; OPHTHALMOLOGY; OSMOLARITY; PHOTOPHOBIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTRATION; REVIEW; SKIN NODULE; TERATOGENICITY; VISUAL DISORDER; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; EYE DISEASES; FEMALE; HUMANS; ISOTRETINOIN; MALE; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 0034887345     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(01)01024-8     Document Type: Article

References (31)

1. Fraunfelder FT, LaBraico JM, Meyer MS. Adverse ocular reactions possibly associated with isotretinoin. Am J Ophthamol 1985;100:534-537.
2. Maclean H, Wright M, Choi D, Tidman MJ. Abnormal night vision with isotretinoin therapy for acne [letter]. Clin Expt Dermatol 1995;20:86.
3. Lerman S. Ocular side effects of accutane therapy. Lens Eye Toxicity Res 1992;9:429-438.
4. Weleber RG, Denman ST, Hanifin JM, Cunningham WJ. Abnormal retinal function associated with isotretinoin therapy for acne. Arch Ophthalmol 1986;104:831-837.
5. Watson NJ. Rod and cone malfunction as a manifestation of isotretinoin therapy - a case report. J Dermatol Treat 1992;3:205-207.
6. World Health Organization (WHO). The WHO Technical Report Series No. 498. International drug monitoring: the role of national centres. Geneva: WHO, 1972.
7. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Safety 1995;10:93-102.
8. Hartmann K, Koller Doser A, Kuhn M. Postmarketing safety information: how useful are spontaneous reports? Pharmacoepid Drug Safety 1999;8:S65-S71.
9. Mathers WD, Shields WS, Sachdev MS, Petroll WM, Jester JV. Meibomian gland morphology and tear osmolarity: changes with accutane therapy. Cornea 1991;10:286-290.
10. Brown RD, Grattan CEH. Visual toxicity of synthetic retinoids. Br J Ophthalmol 1989;73:286-288.
11. Blackman HJ, Peck GL, Olsen TG, Gergsma DR. Blepharoconjunctivitis: a side effect of 130-cis-retinoic acid therapy for dermatologic diseases. Ophthalmology 1979;86:753-758.
12. Milson J, Jone DH, King K, Cunliffe WJ. Ophthalmological effects of 13-cis- retinoic acid therapy for acne vulgaris. Br J Dermatol 1982;107:491.
13. Weiss J, Degnan M, Leupold R, Lumpkin LR. Bilateral corneal opacities. Arch Dermatol 1981;117:182-183.
14. Ensink BW. Ophthalmological side-effects of 13-cis-retinoid therapy. Br J Dermatol 1983;108:627-630.
15. Gold JA, Shupack JL, Nemec MA. Ocular side effects of the retinoids. Intern J Dermatol 1989;23:218-225.
16. McCormack LS, Turner ML. Photosensitivity and isotretinoin therapy. J Am Acad Dermatol 1983;9:273.
17. Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose response study. J Am Acad Dermatol 1984;10:490-496.
18. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985;313:837-841.
19. Weiss, J, Degnan M, Leupold R, Lumpkin LR. Bilateral corneal opacities. Arch Dermatol 1981;117:182-183.
20. Lemp MA. Report of National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes. CLAO 1995;21:221-232.
21. Farrell LN, Strauss JS, Stranieri AM. The treatment of severe cystic acne with 13-cis-retinoic acid: evaluation of sebum production and the clinical response in a multiple-dose trial. J Am Acad Dermatol 1980;3:602-610.
22. Shalita AR. Mucocutaneous and systemic toxicity of retinoids: monitoring and management. Dermatologica 1987;175(suppl 1):151-157.
23. Rismondo V, Ubels JL. Isotretinoin in lacrimal gland fluid and tears. Arch Ophthamol 1987;105:416-420.
24. Roytman M, Frumkin A, Bohn TG. Pseudotumor cerebri caused by isotretinoin. Cutis Nov 1988;42:399-400.
25. Spector RH, Carlisle J. Pseudotumor cerebri caused by a synthetic vitamin A preparation. Neurology 1984;34:1509-1511.
26. Johnson TM, Rapini RP. Isotretinoin thrombocytopenia. J Am Acad Dermatol 1987;17:543-552.
27. Bigby M, Stern RS. Adverse reactions to isotretinoin. J Am Acad Dermatol 1988;18:543-552.
28. Physicians Desk Reference. Montvale, NJ: Medical Economics, 2000:2612.
29. Karel I, Myska V, Kvicalova E. Ophthalmological changes in atopic dermatitis. Acta Derm Venereol 1965;45:381-386.
30. Brunsting LA, Reed WB, Blair HL. Occurrence of cataracts and keratoconus with atopic dermatitis. AMA Arch Dermatol 1955;72:237-241.
31. Herman DC, Dyer JA. Anterior subcapsular cataracts as a possible adverse ocular reaction to isotretinoin. Am J Ophthamol 1987;103:236-237.